Search Results

Viewing Page 3 of 4 | Showing Results 21 - 30 of 35

Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c....

Zachary N. Litvack, MD MCR FAANS

A PHASE 0/1 STUDY OF COMBINATION DRUG THERAPY FOR GLIOBLASTOMA BASED ON PERSONALIZED CANCER STEM CELL (CSC) HIGH-THROUGHPUT DRUG SCREENING

A study to determine the safety of CSC/ HTS-based combination drug therapy in subjects who have GBM that has recurred or progressed following prior...

Charles S. Cobbs, MD

A Multicenter Randomized Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects (REVEAL).

The purpose of this study is to assess the impact of natalizumab (Tysabri) versus fingolimod (Gilenya) on CNS tissue damage and recovery in active...

Peiqing Qian, MD

A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly

The study aims to demonstrate that pasireotide-induced hyperglycemia can be effectively and safely managed in majority of patients, including those...

Kevin Yuen, MD

An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome

The primary objectives of this study are to evaluate the efficacy of ascending doses of COR-003 in subjects with elevated levels of cortisol due to...

Kevin Yuen, MD

ABT-414 Alone or ABT-414 Plus Temozolomide Versus Temozolomide or Lomustine for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group

This study is to evaluate the efficacy and safety of ABT-414 alone or with temozolomide versus temozolomide or lomustine alone in participants with...

Tara Benkers, MD

A multicenter double blind placebo controlled study of montelukast on gastrointestinal tolerability in patients with relapsing forms of multiple sclerosis receiving Tecfidera (dimethyl fumarate) delayed release capsules

A multicenter double blind placebo controlled study of montelukast on gastrointestinal tolerability in patients with relapsing forms of multiple sclerosis receiving Tecfidera (dimethyl fumarate) delayed release capsules

James Bowen, MD

An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)

A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.

Kevin Yuen, MD

A PHASE 3 RANDOMIZED CONTROLLED DOUBLE-ARM OPEN-LABEL MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with...

Tara L. Benkers, MD
Viewing Page 3 of 4 | Showing Results 21 - 30 of 35